Sign In
Buy HCWB
$4.42
-0.130 (-2.86%)
At Close: Jul 13, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
08:25am, Tuesday, 30'th Jun 2026
MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transfor
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
08:55am, Friday, 26'th Jun 2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements fr
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
10:20am, Tuesday, 16'th Jun 2026
HCW Biologics Inc. (NASDAQ:HCWB) stock fell during Tuesday's session. The company announced preliminary results from its Phase 1 trial for HCW9302, an IL-2-based treatment for alopecia areata.
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All particip
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
07:45am, Wednesday, 27'th May 2026
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therape
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
04:02pm, Friday, 22'nd May 2026
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
09:53am, Thursday, 21'st May 2026
MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusi
HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session
11:21pm, Thursday, 14'th May 2026
HCW Biologics Inc. surged 122.55% in after-hours trading after reporting first-quarter EPS that sharply exceeded analyst expectations.
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
04:25pm, Thursday, 14'th May 2026
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transform
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
07:30am, Thursday, 14'th May 2026
HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
04:20pm, Thursday, 30'th Apr 2026
MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fu
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
05:05pm, Tuesday, 31'st Mar 2026
MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fus
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday
02:48am, Wednesday, 25'th Mar 2026
HCW Biologics (NASDAQ: HCWB - Get Free Report) is expected to be announcing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.84) per
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
07:50am, Tuesday, 17'th Mar 2026
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee
